Lung surfactant or Pulmonary surfactant is a mixture of lipids and proteins which is secreted by the epithelial type II cells into the alveolar space. Its main function is to reduce the surface tension at the air/liquid interface in the lung and is essential for breathing.
Premature babies or adults who are seriously ill or injured are highly prone of damage to their lung surfactant, which impairs their ability to breathe. Acute Respiratory Distress Syndrome (ARDS) is one among the disorders caused by lung surfactant damage.
Significance : Many of new potential therapies including small molecules, peptides, proteins, amino acids based agents etc., are facing major problem in their absorption and toxicology profiling. In this scenario, many researchers across world turning towards transmucosal administration of drugs mediated by nanoparticles in particular to pulmonary and nasal routes as a strategy to increase the absorption. Since in-vivo / in-vitro studies to understand absorption ability of given drug / peptide / protein / amino acids based agents etc., is complicated as well as quite expensive, In-silico modeling and simulation of drug / peptide / protein / amino acids based agents of your research interest in presence of pulmonary surfactant mimicking membrane gives you atomic level insights regarding absorption capabilities.
At Innovative Informatica Technologies, using our years of experience in custom modeling and simulations, we have developed the pulmonary surfactant membrane model and offering simulation services to help you understand your research interest compounds' ability to act as transmucosal absorbing agent towards enabling researchers of this domain to use this knowledge to develop artificial lung surfactant based treatments. Contact to discuss further on how our custom modeling and simulation services could be of help in your research.